Astrana signals at least mid-teens adjusted EBITDA growth into 2027 while forecasting 10%-15% Medicaid membership decline (NASDAQ:ASTH)

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B, up from prior periods, with adjusted EBITDA growth expected to reach mid-teens through 2027. CEO Brandon Sim cited growth, margin expansion, and execution. The company forecasts a 10%-15% decline in Medicaid membership.

Original reporting
Published Nov 6, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ASTH
Bullish
medium confidence
Mentioned
$ASTH
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ASTHBullishMed
01

Why it matters

The guidance sets a multi-year earnings trajectory while explicitly flagging Medicaid membership contraction, shaping near-term expectations for revenue mix and risk premium.

02

Market read

Traders can update models around ASTH’s 2027 EBITDA trajectory and Medicaid-driven revenue risk based on the stated guidance ranges.

03

What to watch

Investors may need more detail on reimbursement rates, churn/attrition dynamics, and cost inflation to judge whether EBITDA growth is resilient to Medicaid volume pressure.

Relevance 7/10Novelty 5/10Timing: after-hours earnings call guidance update (Q3 2026)

Background

The piece summarizes Astrana Health’s Q3 2026 earnings call management commentary and forward-looking guidance.

Company-level read

Ticker impact

$ASTHBullishMedium confidence
Context

Astrana Health guided to at least mid-teens adjusted EBITDA growth into 2027 while forecasting a 10% to 15% Medicaid membership decline.

Expected impact

Likely modest support as investors weigh mid-teens EBITDA growth against Medicaid membership decline risk.

Evidence & confidence

The article’s core new decision inputs are multi-year EBITDA growth guidance and a specific Medicaid membership decline forecast, both directly tied to ASTH’s earnings power and risk profile.

Market effects

Could reinforce investor focus on Medicaid membership trends as a key driver of managed-care earnings durability.

No clear regional spillover beyond US Medicaid managed care.

Limited, as the catalyst is US Medicaid membership and company-specific guidance.

Counterpoint

Mid-teens EBITDA growth may rely on margin expansion assumptions that could be harder to sustain if Medicaid membership declines faster than forecast.

Key entities

  • Astrana Health

    Guided to at least mid-teens adjusted EBITDA growth into 2027 and forecast a 10% to 15% Medicaid membership decline.

Related articles

$ASTHHighAI 8/10

Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

$ASTHMed

Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

$ASTHMed

Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

$ASTHHighAI 8/10

Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.

$ASTHMed

Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.